Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory

Abstract: Talquetamab is a G protein–coupled receptor class C group 5 member D–targeting bispecific T-cell engager approved for patients with relapsed multiple myeloma based on the MonumenTAL-1 trial. In this retrospective study of 68 patients, we evaluated safety and efficacy of talquetamab in a re...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Andrew J. Vegel, Bradley T. Loeffler, Jonathan Lochner, Reed Friend, Alma Habib, Marshall McKenna, Jordan Snyder, Kimberly Green, Rachel DiLeo, Gina Patrus, Prerna Mewawalla, Muhammad Umair Mushtaq, Christopher Strouse, Yun Kyoung Ryu Tiger, Nausheen Ahmed, Abdullah M. Khan, Hamza Hashmi, Barry Paul, Shebli Atrash, Al-Ola Abdallah, Hira Shaikh
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2025-06-01
Sarja:	Blood Immunology & Cellular Therapy
Linkit:	http://www.sciencedirect.com/science/article/pii/S3050597625000016
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!